Dennis Christopher John Wesley 4
4 · BIOFORM MEDICAL INC · Filed Feb 19, 2010
Insider Transaction Report
Form 4
Dennis Christopher John Wesley
Director
Transactions
- Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−10,000→ 0 totalExercise: $3.61Exp: 2019-12-10→ Common Stock (10,000 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−4,543→ 0 totalExercise: $3.62Exp: 2019-10-01→ Common Stock (4,543 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−8,053→ 0 totalExercise: $2.06Exp: 2019-07-01→ Common Stock (8,053 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−11,313→ 0 totalExercise: $1.20Exp: 2019-04-01→ Common Stock (11,313 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−14,729→ 0 totalExercise: $1.03Exp: 2019-01-02→ Common Stock (14,729 underlying) - Disposition to Issuer
Director Stock Option (Right to Buy)
2010-02-16−30,000→ 0 totalExercise: $1.10Exp: 2018-12-12→ Common Stock (30,000 underlying)
Footnotes (7)
- [F1]Vine Acquisition Corp. (the "Purchaser"), initiated a tender offer pursuant to Purchaser's offer to purchase all of the outstanding shares of BioForm Medical, Inc. (the "Issuer") at a cash purchase price of $5.45 per share, without interest thereon, and less any applicable withholding taxes, subject to the terms described in the Offer to Purchase filed with the Securities and Exchange Commission on January 15 , 2010 (the "Tender Offer") and the Agreement and Plan of Merger, dated as of December 31, 2009, by and among, Merz GmbH & Co. KGaA, the Purchaser and the Issuer. (Continued in footnote 2).
- [F2]The shares underlying these options, which were accelerated and became vested in connection with the closing of the Tender Offer and the fact that the reporting person ceased to be a director of the Issuer, were canceled in exchange for a cash payment of $18,400.00 representing the number of vested shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
- [F3]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $8,313.69, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
- [F4]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $27,299.67, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
- [F5]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $48,080.25, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
- [F6]The shares underlying these options, which were fully vested at the closing of the Tender Offer, were canceled at the closing of the Tender Offer in exchange for a cash payment of $65,102.18, representing the number of shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.
- [F7]The shares underlying these options, which were accelerated and became vested in connection with the closing of the Tender Offer and the fact that the reporting person ceased to be a director of the Issuer, were canceled in exchange for a cash payment of $130,500.00 representing the number of vested shares of Issuer's common stock underlying such options multiplied by $5.45, less the aggregate exercise price of the options.